China Resources Double-Crane Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 1.18%

China Resources Double-Crane Pharmaceutical Co Ltd (600062) has an Asset Resilience Ratio of 1.18% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥200.64 Million
≈ $29.36 Million USD Cash + Short-term Investments

Total Assets

CN¥17.01 Billion
≈ $2.49 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2000–2023)

This chart shows how China Resources Double-Crane Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check China Resources Double-Crane Pharmaceuti (600062) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down China Resources Double-Crane Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600062 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥200.64 Million 1.18%
Total Liquid Assets CN¥200.64 Million 1.18%

Asset Resilience Insights

  • Limited Liquidity: China Resources Double-Crane Pharmaceutical Co Ltd maintains only 1.18% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

China Resources Double-Crane Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare China Resources Double-Crane Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Bide Pharmatech Co. Ltd. A
SHG:688073
Drug Manufacturers - Specialty & Generic 9.46%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
Drug Manufacturers - Specialty & Generic 5.92%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
Drug Manufacturers - Specialty & Generic 0.00%
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
Drug Manufacturers - Specialty & Generic 9.11%

Annual Asset Resilience Ratio for China Resources Double-Crane Pharmaceutical Co Ltd (2000–2023)

The table below shows the annual Asset Resilience Ratio data for China Resources Double-Crane Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 -0.03% CN¥-4.88 Million
≈ $-714.09K
CN¥15.43 Billion
≈ $2.26 Billion
-1.42pp
2022-12-31 1.38% CN¥200.49 Million
≈ $29.34 Million
CN¥14.48 Billion
≈ $2.12 Billion
-4.49pp
2021-12-31 5.88% CN¥803.58 Million
≈ $117.59 Million
CN¥13.68 Billion
≈ $2.00 Billion
-0.99pp
2020-12-31 6.86% CN¥851.95 Million
≈ $124.67 Million
CN¥12.42 Billion
≈ $1.82 Billion
+0.14pp
2019-12-31 6.72% CN¥758.14 Million
≈ $110.94 Million
CN¥11.28 Billion
≈ $1.65 Billion
-1.80pp
2018-12-31 8.53% CN¥878.68 Million
≈ $128.58 Million
CN¥10.31 Billion
≈ $1.51 Billion
+1.69pp
2017-12-31 6.83% CN¥644.75 Million
≈ $94.35 Million
CN¥9.44 Billion
≈ $1.38 Billion
+5.01pp
2016-12-31 1.82% CN¥150.22 Million
≈ $21.98 Million
CN¥8.24 Billion
≈ $1.21 Billion
-3.44pp
2015-12-31 5.26% CN¥408.65 Million
≈ $59.80 Million
CN¥7.76 Billion
≈ $1.14 Billion
-2.29pp
2014-12-31 7.55% CN¥500.00 Million
≈ $73.17 Million
CN¥6.62 Billion
≈ $968.61 Million
+7.55pp
2005-12-31 0.00% CN¥120.00K
≈ $17.56K
CN¥3.81 Billion
≈ $558.00 Million
+0.00pp
2001-12-31 0.00% CN¥2.60K
≈ $380.46
CN¥2.75 Billion
≈ $401.87 Million
-6.63pp
2000-12-31 6.63% CN¥98.38 Million
≈ $14.40 Million
CN¥1.48 Billion
≈ $217.18 Million
--
pp = percentage points

About China Resources Double-Crane Pharmaceutical Co Ltd

SHG:600062 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.60 Billion
CN¥17.77 Billion CNY
Market Cap Rank
#5288 Global
#915 in China
Share Price
CN¥17.11
Change (1 day)
-0.29%
52-Week Range
CN¥15.60 - CN¥21.22
All Time High
CN¥33.06
About

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 an… Read more